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AbsTrACT
background Non- communicable diseases (NCDs) are the 
leading cause of death globally. In 2014, the United Nations 
committed to reducing premature mortality from NCDs, 
including by reducing the burden of healthcare costs. 
Since 2014, the Prospective Urban and Rural Epidemiology 
(PURE) Study has been collecting health expenditure data 
from households with NCDs in 18 countries.
Methods Using data from the PURE Study, we estimated 
risk of catastrophic health spending and impoverishment 
among households with at least one person with NCDs 
(cardiovascular disease, diabetes, kidney disease, cancer 
and respiratory diseases; n=17 435), with hypertension 
only (a leading risk factor for NCDs; n=11 831) or with 
neither (n=22 654) by country income group: high- income 
countries (Canada and Sweden), upper middle income 
countries (UMICs: Brazil, Chile, Malaysia, Poland, South 
Africa and Turkey), lower middle income countries (LMICs: 
the Philippines, Colombia, India, Iran and the Occupied 
Palestinian Territory) and low- income countries (LICs: 
Bangladesh, Pakistan, Zimbabwe and Tanzania) and China.
results The prevalence of catastrophic spending and 
impoverishment is highest among households with 
NCDs in LMICs and China. After adjusting for covariates 
that might drive health expenditure, the absolute risk of 
catastrophic spending is higher in households with NCDs 
compared with no NCDs in LMICs (risk difference=1.71%; 
95% CI 0.75 to 2.67), UMICs (0.82%; 95% CI 0.37 to 1.27) 
and China (7.52%; 95% CI 5.88 to 9.16). A similar pattern 
is observed in UMICs and China for impoverishment. A high 
proportion of those with NCDs in LICs, especially women 
(38.7% compared with 12.6% in men), reported not taking 
medication due to costs.
Conclusions Our findings show that financial protection 
from healthcare costs for people with NCDs is inadequate, 
particularly in LMICs and China. While the burden of NCD 
care may appear greatest in LMICs and China, the burden 
in LICs may be masked by care foregone due to costs. The 
high proportion of women reporting foregone care due to 
cost may in part explain gender inequality in treatment of 
NCDs.
Key questions
What is already known?
 ► Worldwide, there is low use of drugs for secondary 
prevention of cardiovascular disease and hyperten-
sion, and there is a gender and socioeconomic gap 
in use of treatment.
 ► Research has suggested that out- of- pocket expen-
diture for non- communicable disease (NCD) health-
care can impose a significant burden on households 
but highlighted scarcity of research from sub- 
Saharan Africa, Latin America and the Middle East.
What are the new findings?
 ► Households with NCDs in lower middle income 
countries (LMICs) spend more on healthcare and 
are at greater risk of catastrophic expenditure and 
impoverishment than households without after ad-
justment for potential confounders.
 ► An alarmingly large number of individuals with NCDs 
report not taking prescribed medicines for NCDs due 
to cost, particularly among women in low- income 
countries (LICs).
What do the new findings imply?
 ► Insufficient progress has been made towards inter-
national goals, and we are far from achieving finan-
cial risk protection for people with NCDs, particularly 
in LMICs and LICs.
 ► While the burden of NCD care may appear greatest 
in LMICs, the burden in LICs may be disguised by 
foregone care due to costs, with women likely most 
dramatically affected.
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bACKground
In September 2018, the United Nations (UN) held 
the Third High Level Meeting on the Control of Non- 
Communicable Diseases (NCDs). The purpose of the 
meeting was to track progress towards four commitments 
made in the 2014 UN Outcome Document on NCDs.1 
Among these was a commitment to ‘strengthen and orient 
health systems to address the prevention and control of 
NCDs… through people- centred primary health care 
and universal health coverage (UHC)’, echoing the UN 
Sustainable Development Goal 3, Target 8, to achieve 
UHC for all. Progress towards this commitment will be 
judged by an indicator assessing whether member states 
are providing ‘drug therapy and counseling for eligible 
persons at high risk to prevent heart attacks and strokes’.1
Evidence collected prior to 2014 highlighted why these 
commitments were so urgently needed.2 This showed 
low use of drugs for secondary prevention of cardiovas-
cular disease (CVD; the leading cause of morbidity and 
mortality among NCDs) and hypertension (HTN; the 
most common risk factor) worldwide, and these drugs 
were unavailable and unaffordable to many people in 
lower income countries (LICs).3–6 Out- of- pocket (OOP) 
costs for counselling and drug therapy for CVD and 
related conditions such as HTN, angina or diabetes 
imposed a significant economic burden on households, 
driving some into poverty and, in many cases, were a 
reason for not seeking or adhering to care.7–11 The 
evidence also suggested a gender gap in secondary treat-
ment of CVD in countries at all levels of development, 
with women less likely to take proven effective treatment 
than men.12 It highlighted how the poor were least likely 
to obtain treatment13 and the devastating impact on 
them of OOP costs.14 Finally, it revealed the scarcity of 
research on this topic from some regions in lower middle 
income countries (LMICs), in particular sub- Saharan 
Africa, Latin America and the Middle East.2
Has the situation improved since the 2014 UN commit-
ments were made? Since 2014, the Prospective Urban and 
Rural Epidemiology (PURE) study has collected data on 
OOP expenditure for NCDs in 18 countries at all levels 
of development, making it the most recent and compre-
hensive dataset on this topic. We set out to estimate the 
burden of OOP costs borne by households containing 
patients with HTN and NCDs, and whether these costs 
are barriers to accessing healthcare.
MeTHods
The Pure study
This paper presents secondary analysis of data from 
the PURE Study. PURE is a large ongoing international 
cohort study of NCD incidence, mortality and risk 
factors15 in individuals from urban and rural communi-
ties in 21 countries, with data needed for this analysis 
available from 18 countries: Canada, Sweden, Brazil, 
Chile, Malaysia, Poland, South Africa, Turkey, China, the 
Philippines, Colombia, Iran, the Occupied Palestinian 
Territory (OPT), Bangladesh, India, Pakistan, Zimbabwe 
and Tanzania.
Data collection in PURE has been described in detail 
elsewhere.15 Briefly, in each country, communities were 
selected to achieve a mix of rural and urban popula-
tions while ensuring feasibility of data collection (eg, 
processing blood samples) and long- term follow- up. 
Households were selected to be representative of the 
sociodemographic composition of communities, and 
the sociodemographic characteristics and death rates of 
the samples of the first 17 participating countries were 
similar to national populations.16 Further details on the 
representativeness of the PURE cohort are included as 
online supplementary appendix 1. Within each selected 
household, all individuals aged 35–70 years were eligible 
to participate. Baseline data collection, using a stan-
dardised questionnaire including information on socio-
demographic characteristics and health status, occurred 
between 2005 and 2014, depending on when the country 
joined the PURE Study.15 The round of follow- up data 
collection that included health expenditures began 
in 2014, and the year in which follow- up data were 
completed in each country is shown in online supple-
mentary appendix 2. 15 17 18
study design
Household-level analysis: catastrophic spending and 
impoverishment
Our objective was to compare the economic burden 
of direct OOP health expenditure in households with 
NCDs, HTN and households with neither.
NCD households were defined as those with at least 
one member with CVD (defined as self- reported history 
of stroke, heart attack, angina, other CVD at baseline or 
follow- up), diabetes (self- report of diagnosis or being 
prescribed treatment at follow- up), cancer (self- reported 
history of any cancer at baseline or follow- up), respira-
tory diseases (self- reported history of asthma or chronic 
obstructive pulmonary disease at baseline or follow- up) 
and kidney disease (self- reported history of kidney 
disease or treatment at follow- up only). Households 
with HTN only were defined as those with at least one 
member who self- reported diagnosis or being prescribed 
treatment at follow- up. Baseline HTN or diabetes was not 
used to define our sample as there was a small percentage 
of people in each country (from 0.1% to 4.5%) without 
NCDs who self- reported HTN or diabetes at baseline 
but not at follow- up (online supplementary appendix 
3). These people were not included in our definition 
of having an NCD or HTN (but were included in the 
non- NCD/HTN group if their household had no other 
NCDs). Overall, loss to follow- up in the PURE Study 
was 4.4%. The number of households that either did 
not respond to the expenditure questionnaire, or were 
lost to follow- up, by country income group, is shown in 
online supplementary appendix table 4. Of the 70 346 
households that completed follow- up, our analytical 
sample includes only those households (n=51 920) that 
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completed the expenditure questionnaire (73.8%). The 
number of NCD households in this analysis was n=17 435, 
of HTN households it was 11 831 and non- NCD/HTN 
households numbered 22 654.
The PURE follow- up questionnaire included a module 
on household expenditure based on the WHO World 
Health Survey instrument.19 Expenditures reported 
for the last month included consultation fees paid to 
doctors/nurses, or traditional/alternative healers, diag-
nostic or laboratory tests, medication and ambulance 
costs. Those reported for the last year included costs asso-
ciated with overnight stays in a hospital/health facility or 
a long- term facility (reported for the last year). Expen-
ditures reimbursed by insurance were not included nor 
were insurance premiums. All reported annual expendi-
tures were converted to monthly amounts and to adjusted 
to a common base year and currency for which exchange 
rates were available for all included countries (2011 inter-
national dollar).
We compared NCD households and HTN- only house-
holds with non- NCD households on the following 
measures: (1) mean OOP health expenditure as a 
percentage of effective income; (2) proportion of house-
holds experiencing catastrophic healthcare spending; 
and (3) proportion of households impoverished. We 
defined these measures using definitions used by the 
WHO European Region and described in the 2017 
WHO/World Bank (WB) UHC Global Monitoring 
Report20 and elsewhere.21 Specifically, effective income 
is defined as per capita total expenditure remaining 
after deducting an estimated amount for basic needs 
(estimated as per capita spending on food, housing and 
utilities of those households in the 25th–35th percentile 
of total per capita expenditure).21 22 Catastrophic health-
care spending was defined as cases where per capita 
OOP health expenditures were ≥40% of per capita effec-
tive income. Impoverished households were defined as 
those whose total per capita expenditure gross of per 
capita OOP healthcare expenditure was above the basic 
needs line, but total per capita expenditure net of OOP 
per capita healthcare expenditure was below it. See 
online supplementary appendix 5 for additional tech-
nical details on impoverishment. These definitions were 
selected to ensure maximum comparability of our study 
findings with other external estimates given that these 
are the most widely used definitions globally. Prior to 
calculating these measures, outlier per capita household 
total and healthcare expenditures were ‘top- coded’ (ie, 
converted to the value of the 99th percentile of expendi-
ture for that category).23
A crude comparison of the economic burden of OOP 
costs in NCD households, HTN- only households and 
non- NCD/HTN households would ignore other drivers 
of healthcare expenditure, such as the proportion of 
elderly people living in the household. To account for 
this, we employed multilevel multivariable regression, 
adjusting for the potential influence of community (as 
a random effect), country and the following household 
characteristics (as fixed effects): age composition 
(proportion >60 years of age, proportion <5 years of age), 
gender composition, household size, highest educa-
tion level attained in the household (primary/none/
unknown vs secondary vs tertiary), proportion of the 
household employed, whether any of the NCD or HTN 
patients were women and the highest degree of physical 
impairment caused by the NCD (a continuous measure 
based on the sum of seven binary questions regarding 
the effect of the disease on the patients’ ability to use 
their fingers to grasp, walk without a cane/walker, bend 
down to pick up objects, read or resolve small objects 
on a plate, see a person from across a room, speak and 
hear conversations). We compared the risk difference in 
the percentage of effective income spent on healthcare, 
the percentage of households experiencing catastrophic 
spending and the percentage of households experiencing 
impoverishment, adjusted for the above household char-
acteristics, between NCD and HTN- only households 
compared with non- NCD/HTN households. We hypoth-
esised that risk increased with condition severity (ie, 
from non- NCD/non- HTN to HTN- only to NCD) and 
conducted regression- based tests for linear trend.
Individual-level analysis: financing sources and cost as a barrier to 
treatment
Individuals with NCDs and HTN in PURE were asked 
about challenges they faced in adhering to treatment due 
to cost and about sources of financing of health expendi-
ture. We estimated the individual- level self- reported prev-
alence of not taking prescribed medicines due to cost (‘In 
the past 12 months, was there a time when you did not 
take prescribed medicines due to cost?’), self- reported 
difficulties paying for healthcare (‘In the last 12 months 
have you experienced difficulty paying for doctor’s fees/
medications/diagnostic fees/hospital bills?’) and the 
use of different sources of financing (eg, using savings, 
borrowing money and selling assets) to pay for health 
expenditures (‘In the last 12 months, how did you usually 
pay for medical/health care costs?’), among individuals 
with NCDs (n=21 934) and HTN (n=17 512).
All results are presented by country income groupings, 
according to World Bank classifications20: high- income 
countries (HICs: Canada and Sweden), upper middle 
income countries (UMICs: Brazil, Chile, Malaysia, 
Poland, South Africa and Turkey), LMICs (the Phil-
ippines, Colombia, India, Iran and the OPT) and low- 
income countries (LICs: Bangladesh, Pakistan, Zimbabwe 
and Tanzania). Where means are presented, they are 
calculated across all individuals within the country 
income category. China, an UMIC, is presented sepa-
rately as it has a much larger sample size than any other 
group of countries. Other country- specific results can 
be found in online supplementary appendix 6. We also 
conducted a sensitivity analysis using regional grouping 
(South Asia: India, Pakistan and Bangladesh; Canada/
Sweden; South America: Brazil, Chile and Colombia; 
China; South East Asia: Malaysia and the Philippines; 
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Middle East: Saudi Arabia, Iran, United Arab Emirates 
(UAE) and Turkey; and sub- Saharan Africa: South Africa, 
Tanzania and Zimbabwe) to see if the different grouping 
makes a difference to the interpretation of results from 
the country income group analysis. These results can be 
found in online supplementary appendix 7. All analyses 
were conducted using Stata V.15.
Patient and public involvement statement
Patients were not involved in this study.
resulTs
Table 1 shows descriptive statistics of households in our 
sample by country income group. On average, NCD and 
HTN- only households tended to be older than other 
households, and in every country income group except 
for LICs, a higher proportion of the household was 
employed. NCD households in LMICs, LICs and in China 
tended to be better educated than the HTN- only and 
non- NCD/HTN households, consistent with findings 
from some other NCD and NCD risk factors (eg, physical 
inactivity) studies in these settings.24–26
Figure 1 shows the unadjusted comparison of mean 
household healthcare expenditure as a percentage of 
effective income, proportion of households experiencing 
catastrophic spending and proportion impoverished, 
across the three types of household. Households with at 
least one member with a NCD spend a higher percentage 
of their effective income on healthcare than HTN- only 
and non- NCD/HTN households, and differences are 
greatest in LMICs (NCD households: 12.0%; HTN only: 
7.8%; non- NCD/HTN: 6.0%) and China (NCD house-
holds: 16.3%; HTN only: 11.4%; non- NCD/HTN: 5.8%). 
Catastrophic spending appears higher among NCD 
households in all country income groups apart from 
LICs and of impoverishment apart from HICs and LICs. 
Country specific results (online supplementary appendix 
6) show highest percentages of catastrophic spending in 
Bangladesh (22.2%), Poland (21.9%) and Iran (14.7%) 
and the lowest in Malaysia (0.9%), Colombia (0.9%) and 
Turkey (1.8%). We also include a breakdown of average 
household monthly expenditure in NCD households by 
type of expenditure in online supplementary appendix 
table 7. In each country income group and China, the 
biggest driver of health expenditure was medicines, 
except for in LICs where it was diagnostics.
Table 2 shows the mean difference in percentage of 
effective income spent on healthcare, and the differ-
ence in risk of experiencing catastrophic spending and 
impoverishment, comparing NCD households or HTN 
households to non- NCD households, with 95% CIs, after 
adjusting for potentially confounding household charac-
teristics. The presence of an NCD or HTN in a household 
increases the percentage of effective income spent on 
healthcare in LMICs, with NCD households spending on 
average 3.55% and HTN- only households 0.94% more 
than non- NCD households (p for trend <0.001) and 
in China (NCD households: 7.89%; HTN households: 
4.24%; p<0.001). A similar pattern was observed in HICs, 
UMICs and LICs but with less dramatic increases. The risk 
of catastrophic spending from non- NCD/HTN to HTN 
only to NCD households increases significantly in all 
country income groups except for LICs, with the highest 
risk among NCDs households in China (risk difference: 
7.52%). There is also a statistically significant increasing 
trend in risk of impoverishment in UMICs (risk difference 
for NCD households: 0.34%) and China (risk difference: 
1.15%). As a sensitivity analysis, we reproduced table 2 
using different country groupings by region (South Asia: 
India, Pakistan and Bangladesh; Canada/Sweden; South 
America: Brazil, Chile and Colombia; China; South East 
Asia: Malaysia and the Philippines; Middle East: Saudi 
Arabia, Iran, UAE and Turkey; and sub- Saharan Africa: 
South Africa, Tanzania and Zimbabwe). Results are shown 
in online supplementary appendix table 8. Our find-
ings hold even with the different groupings, with NCD 
households at greater odds of catastrophic spending in 
all regions, with the highest odds experienced by NCD 
households in China, sub- Saharan Africa and South Asia.
Table 3 presents the proportion of individuals with 
NCDs and HTN reporting cost as a reason for not taking 
prescribed medicine, and reporting difficulty paying for 
various categories of healthcare costs, by gender. Each 
indicator was reported more commonly by women than 
men, in each country income group apart from in China, 
but numbers were very high for both genders. Most 
alarmingly, 38.7% of female NCD respondents in LICs 
reported not taking medicines in the last year because 
of cost, compared with 12.6% of males. Also, more than 
a third of female NCD and HTN respondents in LICs 
reported difficulties paying for every category of health-
care cost. These numbers were also very high in LMICs, 
where around a quarter of female NCD and HTN respon-
dents reporting difficulty paying for medications.
Table 4 shows the proportion of individuals who have 
NCDs and HTN (and who responded to this question) 
reporting four types of coping strategies. Reimbursement 
from insurance was not included as, in that case, the 
individual or their family were not making the payment. 
While using income or savings was the most common in 
all country income groups, borrowing money from family 
or friends also appears important in LICs (NCD respon-
dents: 12.8%; HTN only: 7.6%) and in LMICs (NCD 
respondents: 10.1%; HTN only: 7.0%). In LICs, selling 
items was reported by 5.9% of NCD respondents and 
11.3% of HTN- only respondents.
disCussion
The primary goal of the 2014 UN commitments on NCDs 
is to protect people from dying prematurely from heart 
and lung diseases, cancers and diabetes. To achieve this 
aim, the WHO Global Action Plan for the Prevention 
and Control of NCDs stresses the importance of ensuring 
affordable access to early diagnosis and treatment for 
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Figure 1 Economic burden of healthcare costs, comparing NCD, HTN only and non- NCD/HTN households by country income 
group, PURE Study. HIC, high- income country; LIC, lower income country; LMIC, lower middle income country; NCD, non- 
communicable disease; PURE, Prospective Urban and Rural Epidemiology; UMIC, upper middle income country.
those with NCDs.27 Our paper represents the first multi-
country estimates since 2014 of the burden of health-
care costs faced by households with NCDs, using current 
global standards of economic burden measurement and 
a consistent approach across a sample of countries at 
different levels of development. Our analysis shows that 
we are far from realising this goal; households with NCDs 
and HTN experience a higher burden of healthcare than 
those without NCDs, and in LICs, the burden may be 
disguised by foregone care.
After adjusting for factors that might drive house-
hold health expenditure, we find that households with 
NCDs experience statistically significantly higher risk of 
catastrophic spending than non- NCD/HTN households 
in all country income groups except for LICs, with the 
highest risk in LMICs and China. They also have statis-
tically significantly higher risk of impoverishment in 
UMICs, LMICs and China. Greater risk is also observed 
in households with HTN only, but these are more 
modest. This may be because HTN is a silent condition 
often untreated and not incurring expenditures. Indeed 
only 6.5% of people with HTN in African PURE coun-
tries and only 18.4% in North American and European 
PURE countries have their HTN controlled.28 Treatment 
of HTN is also inherently less expensive than treatment 
for most NCDs, which usually requires multiple medica-
tions and more frequent visits to the health facility. This 
likely explains the lower financial risk in the HTN group. 
This also emphasises the benefits of intervening early 
with HTN to prevent complications and to reduce the 
economic burden.
While the higher economic burden in LMICs compared 
with LICs may appear surprising, this is consistent with 
other evidence that people initially pay more OOP as 
countries become richer, with OOP only falling again as 
they progress to UMICs and HICs.29 In the poorest coun-
tries, households are more likely to forgo care because 
they simply cannot afford it. This, paradoxically, reduces 
catastrophic spending and impoverishment on care.30
In LICs, patients with NCDs may finance healthcare 
expenditures by borrowing from family or friends, as we 
show here (12.8% of people). This is intuitive as many 
households in these countries will be unable to pay 
large sums from current income or savings,31 32 thereby 
causing them to seek alternative strategies.32 33 Although 
borrowing may allow households to pay for care for short 
periods, it can conceal potential longer term economic 
consequences when loans need to be repaid,33 or impact 
on treatment adherence when healthcare costs are 
chronic and recurring, as in the case of NCDs. As such, 
cross- sectional studies are limited in their capacity to 
estimate the true economic impact of healthcare costs 
on households who employ such coping strategies in 
the short term.34 It is important to consider how house-
holds finance OOP health expenditures when designing 
methods to monitor financial risk protection.32
The impact that OOP can have on treatment adher-
ence is evident in our findings, and this appears to affect 
women more than men in LICs. More than 30% of women 
in LIC reported that they did not take medications 
in the last year due to cost and that they had difficulty 
paying for doctor’s fees, medications, diagnostic fees and 
hospital bills. This may in part explain why fewer women 
are using effective treatment for conditions like CVD.12 
Research from several African countries has shown that 
women are more likely than men in the highest income 
group to use healthcare but that the reverse is true in 
the lowest income groups.35 In households where the 
male is the sole breadwinner, his falling ill is likely to 
have a larger impact on income than when a woman falls 
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ill.36 Consequently, healthcare of male members of the 
household may be prioritised over females. However, 
other factors play a part, including lower literacy,37 less 
autonomy,38 less disposable income39 and less control 
over household financial resources.40 This gender gap 
emphasises the urgency of UHC as a pathway to equity 
in health.
limitations
Earlier work has suggested that health- focused surveys, 
such as the WHO World Health Survey41 from which the 
PURE Study expenditure module was adapted, which 
include only brief modules on general (ie, non- health 
care) expenditure, can overestimate the burden of health-
care expenditure on households,42 due to some general 
expenditure items being missed or the participants’ 
attention being drawn more to their health expenditure. 
The PURE Study may be vulnerable in this way, and our 
figures for catastrophic spending and impoverishment 
among NCD households are higher than previous find-
ings from the general population.43 44 However, if we are 
indeed underestimating general expenditure, this would 
affect NCD, HTN and non- NCD households equally, so 
this should not affect our estimates of the differences in 
catastrophic spending or impoverishment.
There is substantial debate about the most appropriate 
measures of catastrophic spending and impoverish-
ment,22 and our choice for the main analyses may be crit-
icised by proponents of alternative approaches. However, 
online supplementary appendix 5 presents all the alter-
natives used in the WB/WHO UHC Tracking Report, and 
while the observed magnitude of each indicator differs, 
as expected, the pattern is the same, revealing a consis-
tently higher burden among NCD households versus 
non- NCD households, particularly in LMICs. Regard-
less of the measure used, our estimates of economic 
burden are limited in that they include only one aspect 
of economic burden, that is, healthcare expenditures, 
and do not capture the indirect burden caused by loss of 
productivity and wages due to ill health.
Our analysis relied on self- reported health data, which 
can be subject to reporting bias. However, in the PURE 
Study, self- reported information on death, myocardial 
infarction, stroke, heart failure, cancer, hospitalisations, 
new diabetes, chronic obstructive pulmonary disease and 
several other acute conditions was adjudicated centrally 
in each country by trained physicians using standardised 
definitions. For example, self- reported CVD events 
were verified against medical or hospital records in 455 
reported events, with a confirmation rate of 89%. Further 
follow- up has shown that mortality among those with self- 
reported coronary heart disease or stroke is 4–6 times 
that of the population without, serving as a measure 
of the validity of the self- reports. With respect to HTN, 
the accuracy of self- reported diagnosis has been shown 
by a number of studies, and the use of self- reported 
HTN treatment or diagnosis to define HTN prevalence 
is supported by the World Hypertension League.45 Our 
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analysis includes many of the most common NCDs; it 
does not include the full range of NCDs that cause finan-
cial hardship for patients’ households. The healthcare 
costs associated with other NCDs, for example, mental 
disorders, is also likely to contribute to the financial 
burden faced by households.46
Finally, the PURE Study’s design as a cohort study neces-
sitated inclusion of subjects in communities who could 
feasibly and affordably be followed up over many years. 
As such, the sampling framework in each country was 
not designed to be nationally representative. However, 
the PURE Study household sample has showed good 
concordance with the national age, sex, place of resi-
dence (urban/rural), education and mortality profiles of 
the study countries, suggesting that there was no systemic 
bias in data collection.16 As mentioned above, further 
information on the representativeness of the PURE Study 
cohort is included as online supplementary appendix 1.
ConClusion
Our findings show that we are far from achieving finan-
cial risk protection for people with NCDs, particularly 
in LMICs and LICs. While the burden of NCD care may 
appear greatest in LMICs, the burden in LICs may be 
disguised by foregone care due to costs. Females with 
NCDs are most markedly affected by OOP for NCD care, 
contributing to gender inequality in treatment. At a time 
when the international community is reviewing progress 
towards mutually agreed NCD goals, the data summa-
rised in this paper highlight the need for urgent solu-
tions, taking a gendered perspective, to make NCD care 
more accessible to all.
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